{"id":18737,"date":"2023-05-16T22:43:00","date_gmt":"2023-05-16T14:43:00","guid":{"rendered":"https:\/\/flcube.com\/?p=18737"},"modified":"2024-12-18T22:45:24","modified_gmt":"2024-12-18T14:45:24","slug":"lynk-pharmaceuticals-lnk01001-demonstrates-efficacy-in-phase-ii-rheumatoid-arthritis-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=18737","title":{"rendered":"Lynk Pharmaceuticals’ LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study"},"content":{"rendered":"\n

China-based Lynk Pharmaceuticals Co., Ltd announced positive results from the Phase II clinical study of its drug candidate LNK01001 in treating rheumatoid arthritis (RA). The study demonstrated a statistically significant efficacy difference in terms of primary and key secondary endpoints, along with a favorable safety and tolerability profile.<\/p>\n\n\n\n

LNK01001: A JAK1 Inhibitor with Broad Potential<\/strong>
LNK01001, a JAK1 inhibitor, is currently in Phase II clinical studies for additional indications, including ankylosing spondylitis and atopic dermatitis. The JAK\/STAT signaling pathway, which LNK01001 targets, is recognized as a central communication node in cellular function, playing a crucial role in regulating various cellular mechanisms. Increasing evidence suggests that this pathway is associated with a range of autoimmune diseases, making JAK inhibitors a promising class of drugs for treatment.<\/p>\n\n\n\n

Growing Market for JAK Inhibitors<\/strong>
The market for JAK inhibitors is anticipated to reach a value of USD 30.5 billion by 2030, according to a report by Frost & Sullivan. This growth is driven by the broad potential of JAK inhibitors in treating various autoimmune diseases and inflammatory conditions, positioning companies like Lynk Pharmaceuticals at the forefront of innovative drug development in this space.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Lynk Pharmaceuticals Co., Ltd announced positive results from the Phase II clinical study of…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,17,1351],"class_list":["post-18737","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-results","tag-lynk-pharmaceuticals"],"yoast_head":"\nLynk Pharmaceuticals' LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Lynk Pharmaceuticals Co., Ltd announced positive results from the Phase II clinical study of its drug candidate LNK01001 in treating rheumatoid arthritis (RA). The study demonstrated a statistically significant efficacy difference in terms of primary and key secondary endpoints, along with a favorable safety and tolerability profile.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=18737\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lynk Pharmaceuticals' LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=18737\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-16T14:43:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-18T14:45:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18737#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18737\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lynk Pharmaceuticals’ LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study\",\"datePublished\":\"2023-05-16T14:43:00+00:00\",\"dateModified\":\"2024-12-18T14:45:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18737\"},\"wordCount\":203,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Clinical trial results\",\"Lynk Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18737#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18737\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=18737\",\"name\":\"Lynk Pharmaceuticals' LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-05-16T14:43:00+00:00\",\"dateModified\":\"2024-12-18T14:45:24+00:00\",\"description\":\"China-based Lynk Pharmaceuticals Co., Ltd announced positive results from the Phase II clinical study of its drug candidate LNK01001 in treating rheumatoid arthritis (RA). The study demonstrated a statistically significant efficacy difference in terms of primary and key secondary endpoints, along with a favorable safety and tolerability profile.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18737#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18737\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18737#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lynk Pharmaceuticals’ LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lynk Pharmaceuticals' LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study - Insight, China's Pharmaceutical Industry","description":"China-based Lynk Pharmaceuticals Co., Ltd announced positive results from the Phase II clinical study of its drug candidate LNK01001 in treating rheumatoid arthritis (RA). The study demonstrated a statistically significant efficacy difference in terms of primary and key secondary endpoints, along with a favorable safety and tolerability profile.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=18737","og_locale":"en_US","og_type":"article","og_title":"Lynk Pharmaceuticals' LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=18737","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-05-16T14:43:00+00:00","article_modified_time":"2024-12-18T14:45:24+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=18737#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=18737"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lynk Pharmaceuticals’ LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study","datePublished":"2023-05-16T14:43:00+00:00","dateModified":"2024-12-18T14:45:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=18737"},"wordCount":203,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Clinical trial results","Lynk Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=18737#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=18737","url":"https:\/\/flcube.com\/?p=18737","name":"Lynk Pharmaceuticals' LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-05-16T14:43:00+00:00","dateModified":"2024-12-18T14:45:24+00:00","description":"China-based Lynk Pharmaceuticals Co., Ltd announced positive results from the Phase II clinical study of its drug candidate LNK01001 in treating rheumatoid arthritis (RA). The study demonstrated a statistically significant efficacy difference in terms of primary and key secondary endpoints, along with a favorable safety and tolerability profile.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=18737#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=18737"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=18737#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lynk Pharmaceuticals’ LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18737","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18737"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18737\/revisions"}],"predecessor-version":[{"id":18738,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18737\/revisions\/18738"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18737"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18737"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18737"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}